Multiple Myeloma: Diagnosis and Treatment Myeloma . Treatment. and
PowerPoint Presentation - Myeloma Academy · VGPR, very good partial response. Bahlis N et al....
20
Transcript of PowerPoint Presentation - Myeloma Academy · VGPR, very good partial response. Bahlis N et al....
CR, complete response; DOR, duration of response; MPT, melphalan-prednisone-thalidomide; PR, partial response; Rd, lenalidomide and low-dose dexamethasone; Rd18, Rd for 18 cycles;
VGPR, very good partial response.
Bahlis N et al. Assessing the Benefit of Continuous Treatment in the FIRST Trial (MM-020): Impact of Response in Patients With Transplant-Ineligible Newly Diagnosed Multiple Myeloma. EHA
2015, abstract #P277.
6
8
LEN MNTCa
(n = 231)PLACEBO(n = 229)
INTERIM ANALYSIS AND UNBLINDING DEC 2009
CROSSOVER BEFORE PD ALLOWED
CONTINUEDTREATMENT ALL TREATMENT
DISCONTINUEDJan 2011
NO CROSSOVER BEFORE PD ALLOWED
LEN: 2 COURSES
LEN MNTCa
(n = 307)PLACEBO(n = 307)
CONTINUED TREATMENT
MPR: 6 COURSES
2 × 2 DESIGNLEN + DEX × 4
INDUCTION
LEN MNTCb
(n = 67)
NO TREATMENT
(n = 68)
LEN MNTCb
NO TREATMENT
ASCT
CONTINUED TREATMENT
CONTINUED TREATMENT
9
0.00 10 20 30 40 50 60 70 80 90 100 110 120
0.2
0.4
0.6
0.8
1.0
605 578 555 509 474 431 385 282 200 95 20 1 0
604 569 542 505 458 425 350 271 174 71 10 0
Overall Survival, mos
Su
rviv
al
Pro
ba
bilit
y
Patients
at risk
7-yr OS
62%
50%
LENALIDOMIDE CONTROL
0.74 (0.62-0.89)
.001
•
•
•
•
•
•
•
•
•
•
